IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwr...
April 04 2019 - 7:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology company today announced that IMV Chief Executive
Officer, Frederic Ors will be making an investor presentation at
the 2019 Bloom Burton & Co Healthcare Investor Conference,
which will be held from April 30 to May 1, 2019 in Toronto,
Ontario.
IMV’s presentation details include:
- Date: Wednesday, May 1,
2019
- Time: 11:00 a.m. ET
- Location: Metro Toronto
Convention Centre, 255 Front St W, Toronto, ON
There will be a live webcast of IMV’s presentation accessible in
the 'Events, Webcasts & Presentations' page of IMV’s website.
The webcast will be archived for 90 days following the live
presentation and a copy of the presentation will be available
www.imv-inc.com.
April 9 H.C. Wainwright Investor Conference Presentation
Update:
IMV also revealed a time change for its participation at the
H.C. Wainwright Global Life Sciences Conference. IMV will now
present at 1:10 p.m. local time. Full details include:
- Venue: H.C. Wainwright Global
Life Sciences Conference, being held April 7-9, 2019
- Date: Tuesday, April 9,
2019
- Time: 1:10 p.m. BST
- Location: Stratton Suite,
Grosvenor House, A JW Marriott Hotel, London, UK
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings
together U.S., Canadian and international investors who are
interested in the latest developments in the Canadian healthcare
sector. Attendees will have an opportunity to obtain corporate
updates from the premier Canadian publicly traded and private
companies through presentations and private meetings.
About Bloom Burton & Co.
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm
dedicated to accelerating returns in the healthcare sector for both
investors and companies. Bloom Burton has an experienced team of
medical, scientific, pharmaceutical, legal and capital markets
professionals who perform a deep level of diligence, which combined
with our creative and entrepreneurial approach, assists our clients
in achieving the right monetization events. Bloom Burton and its
affiliates provide capital raising, M&A advisory, equity
research, business strategy and scientific consulting, advisory on
direct investing and company creation and incubation services.
Bloom Burton Securities Inc. is a member of the Investment Industry
Regulatory Organization of Canada (IIROC) and is also a member of
the Canadian Investor Protection Fund (CIPF).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190404005058/en/
Investor Relations:Marc Jasmin, IMV Senior Director,
Investor Relations and CommunicationsO: (902) 492-1819 ext : 1042M:
(514) 917-9481 E: mjasmin@imv-inc.comMedia:Andrea
Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024